Juan Wang
Jilin University, China
Title: MUC1-MBP/BCG anti-tumor vaccine, an attractive anti-tumor vaccine
Biography
Biography: Juan Wang
Abstract
Mucin 1 (MUC1), as an oncogene, plays a key role in the progression and tumorigenesis of many human adenocarcinomas and is an attractive target in tumour immunotherapy. To develop an effective anti-tumour vaccine for the treatment of MUC1-expressing human tumours, our research group generated a recombinant MUC1-MBP fusion protein combined with Bacillus Calmette-Guerin (MUC1-MBP/BCG) anti-tumour vaccine, the repeated animal experiments demonstrated that MUC1-MBP/BCG anti-tumour vaccine not only induced the release of MUC1-specific antibody and a MUC1-specific Th1-dominant immune response, but also enhanced the cytotoxic T lymphocyte killing activity and the activation of macrophage and NK cells. Furthermore, the results from tumour-bearing nude mouse model revealed that MUC1-MBP/BCG anti-tumor vaccine significantly inhibited the growth of Lewis lung cancer, B16-MUC1 (MUC1+) and human breast cancer cells. To help move the vaccine into a Phase I clinical trial, the pilot production process and quality control standard of pharmaceutical research have been accomplished, and a majority of pharmacodynamics, pharmaceutical and toxicology pre-clinical studies have been accomplished as well. A pre-clinical toxicity evaluation that comprised of a single-dose acute toxicity study in mice, repeat-dose chronic toxicity and immunogenicity studies in rats, and pilot toxicity and immunogenicity studies in cynomolgus monkeys showed that treatment with the MUC1-MBP/BCG anti-tumour vaccine did not cause any organ toxicity. Collectively, these data are beneficial to move the MUC1-MBP/BCG anti-tumour vaccine into a Phase I clinical trial, and suggesting that MUC1-MBP/BCG vaccine is an attractive anti-tumour vaccine.